Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Diabetic Macular Edema Market Overview

The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM (seven major pharmaceutical markets). The market is forecast to achieve a CAGR of more than 8% during the forecast period.

Diabetic Macular Edema is a complication of type 1 and 2 diabetes with diabetic retinopathy. It is a leading cause of visual impairment and blindness in first-world countries, affecting over 28 million people (International Diabetes Federation, 2016; de Moura et al., 2020). The DME research report provides an overview of DME – including epidemiology, disease etiology, and management. The report will help to develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.

Diabetic Macular Edema Market Size

For more insights on this report, download a free report sample

Key Regions in the Diabetic Macular Edema Market

Seven major pharmaceutical markets (7MM) covered in this report are the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. The US has the largest market share.

Diabetic Macular Edema Market, by Regions

DME Market, by RegionsFor more regional insights, download a free report sample

DME Market Drivers

An increase in therapies with a longer duration of action, such as Kodiak Science’s KSI-301, means fewer treatment days, consequently improving patient compliance for DME patients who already experience heavy treatment burdens. In addition, the diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity. Such factors will drive market growth in the coming years.

DME Market Barriers

Expensive therapies will face reimbursement challenges in markets where cost-conscious decisions are increasingly implemented. In addition, the inferior efficacy of pipeline agents will continue to leave many patients without adequate suppression of angiogenesis. This may hamper the growth of the market in focus in the coming years.

Classifications in the DME Market

DME is commonly classified as either focal (fDME) or diffuse (dDME). Diagnostic techniques used to diagnose DME subsets include optical coherence tomography (OCT) and fluorescein angiography (FA).

FDME

fDME involves fluid leaking from dilated capillaries and retinal microaneurysms. This is mainly associated with internal damage of BRB and presents as retinal fluid collection only in the outer retina. fDME may further be characterized by the presence of hard exudates.

DDME

DDME, on the other hand, consists of fluid leaking from the entire foveal circumference. This is mainly associated with external damage to the BRB; extensive capillary leakage leads to retinal fluid collection in the inner retina. dDME patients may also be susceptible to cystoid macular edema.

Key Pipeline Products in the DME Market

Diabetic Macular Edema has Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac in the pipeline.

Key Players in the DME Market

Some of the key players in the Diabetic Macular Edema market are Novartis, Bayer, Alcon, Abbvie, and Regeneron.

Market Report Overview

Market size (2021 in 7MM) $5.05 billion
CAGR (2021 – 2031) >8%
Classifications FDME and DDME
Key Products Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac
Key players Novartis, Bayer, Alcon, Abbvie, and Regenron

Scope

  • Overview of DME – including epidemiology, disease etiology and management.
  • Topline DME drugs market revenue, annual cost of therapy, and anticipated sales for major late-stage pipeline drugs.
  • Key topics covered include assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
  • Pipeline analysis: Emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
  • Analysis of the current and future market competition in the global DME therapeutics market. Insightful review of the key industry drivers and barriers.

Key Highlights

DME market will grow significantly during the forecast period, at a CAGR of 8.2%.

Late-stage pipeline therapies are anticipated to drive growth in the DME market.

Reducing treatment burden is an important unmet need for DME.

Reasons to buy

The report will enable you to:

  • Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
  • Develop business strategies by understanding the trends shaping and driving the global DME therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Diabetic Macular Edema market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global DME therapeutics market from 2021-2031.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

FAQs

  • The Diabetic Macular Edema market size was $5.05 billion in 2021 across the 7MM.

  • The Diabetic Macular Edema market is forecast to achieve a CAGR of more than 8% during the forecast period.

  • The key classifications in the Diabetic Macular Edema market are FDME and DDME.

  • Ranibizumab, Aflibercept, Bevacizumab, Dexamethasone, Fluocinolone Acetonide, Triamcinolone Acetonide, Ranibizumab Biosimilar, and Nepafenac are in the pipeline in DME market.

     

  • Some of the key players in the Diabetic Macular Edema market are Novartis, Bayer, Alcon, Abbvie, and Regeneron.

What our clients have to say

More Reports

View More Reports